These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3029956)

  • 1. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep.
    Huismans H; van der Walt NT; Cloete M; Erasmus BJ
    Virology; 1987 Mar; 157(1):172-9. PubMed ID: 3029956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the serotype-specific and group-specific antigens of bluetongue virus.
    Huismans H; Erasmus BJ
    Onderstepoort J Vet Res; 1981 Jun; 48(2):51-8. PubMed ID: 6273773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype.
    Mertens PP; Pedley S; Cowley J; Burroughs JN; Corteyn AH; Jeggo MH; Jennings DM; Gorman BM
    Virology; 1989 Jun; 170(2):561-5. PubMed ID: 2543130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant virus vaccine for bluetongue disease in sheep.
    Roy P; Urakawa T; Van Dijk AA; Erasmus BJ
    J Virol; 1990 May; 64(5):1998-2003. PubMed ID: 2157868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic response of sheep to inactivated and virulent bluetongue virus.
    Stott JL; Barber TL; Osburn BI
    Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency and efficacy of inactivated bluetongue virus vaccines.
    Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
    Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro neutralization of antigenic variants of bluetongue virus is related to in vivo protection.
    Sundin DR; Dean VC; DuBard KM; Mecham JO
    Viral Immunol; 1989; 2(3):195-203. PubMed ID: 2560915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal development of bluetongue virus protein-specific antibody in sheep following natural infection.
    Adkison MA; Stott JL; Osburn BI
    Vet Microbiol; 1988 Mar; 16(3):231-41. PubMed ID: 2836995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformationally dependent epitopes of bluetongue virus neutralizing antigen.
    Grieder FB; Schultz KT
    Viral Immunol; 1989; 2(1):17-24. PubMed ID: 2472808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dot immunobinding assay for the detection of bluetongue virus antibodies in sheep experimentally inoculated with bluetongue virus type 1.
    Chander S; Prasad G; Jain NC
    Vet Microbiol; 1991 Aug; 28(3):289-94. PubMed ID: 1654670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response against the purified serotype specific antigen of bluetongue virus and initial attempts to clone the gene that codes for the synthesis of this protein.
    Huismans H; van der Walt NT; Erasmus BJ
    Prog Clin Biol Res; 1985; 178():347-53. PubMed ID: 2989871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies to bluetongue virus define two neutralizing epitopes and a hemagglutinating epitope.
    Mecham JO; Jochim MM
    Viral Immunol; 1990; 3(2):161-70. PubMed ID: 1694430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of neutralising antibody in passive immunity to bluetongue infection.
    Jeggo MH; Wardley RC; Taylor WP
    Res Vet Sci; 1984 Jan; 36(1):81-6. PubMed ID: 6324311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental bluetongue infections in gnotobiotic lambs and kids.
    Livingston CW; McConnell S; Cummings G; Gauer BB
    Am J Vet Res; 1983 Jan; 44(1):129-31. PubMed ID: 6297338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
    Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine.
    Huismans H
    Onderstepoort J Vet Res; 1985 Sep; 52(3):149-51. PubMed ID: 3003649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.
    White JR; Eaton BT
    J Gen Virol; 1990 Jun; 71 ( Pt 6)():1325-32. PubMed ID: 1693664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.